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C
ytokines are protein mediators of intercellular
stress communication with autocrine, paracrine,
and endocrine modes of action. Hormones differ
from cytokines by being produced in specialized
glandular organs, by not all being proteins, and by their
homeostatic properties. Virtually all nucleated cells pro-
duce and respond to cytokines under deﬁned conditions,
mainly in response to stress signals and in parallel to their
differentiated functions. The cytokine group of molecules
encompasses several hundred individual protein moieties,
including 37 interleukins (ILs) and a multitude of chemo-
kines. Many of these molecules have redundant functions
whereas others elicit speciﬁc cellular reactions. It is de-
bated whether cytokines also have homeostatic proper-
ties, i.e., contribute to the maintenance of normal cellular
physiology.
Cytokines are central mediators of inﬂammation by con-
troling innate and adaptive immune responses as well as
tissue damage, defense, repair, and remodeling. Type 1 di-
abetes is an inﬂammatory disease of the pancreatic islet, in
which insulin-producing b-cells are preferentially destroyed
to varying degrees by the concerted action of autoreactive
T-cells and monocytic cells (1). Despite huge research ef-
forts over the past 40 years, no therapy targeting pathoge-
netic events in type 1 diabetes has attained routine clinical
utility. A number of cytokines have been shown to be im-
portant for the development of type 1 diabetes both at the
level of the immune system and at the level of the target
b-cells (2,3). The actual mechanism of b-cell destruction is
still unclear, and classical T-cell effector pathways as well
as many proinﬂammatory cytokines have been proven dis-
pensable in transgenic animal models. Only a few inﬂam-
matory proteins have been demonstrated to be critical for
type 1 diabetes development in the NOD mouse, one of
which is IL-21, discovered in 2000 by the Foster team at
Zymogenetics. IL-21 is a member of the class I cytokine
receptor-binding cytokine family including leptin, IL-2–7, IL-9,
IL-11–13, and IL-15 (4) and signals via the JAK-STAT3
pathway to drive immunoglobulin production and pro-
liferation of T- and B-cells as well as natural killer cells.
In 2008, Spolski et al. (5) showed near-complete pre-
vention of insulitis and diabetes in IL-21R–deﬁcient NOD
mice associated with reduced numbers and function of
t h eh i g h l yp r o i n ﬂammatory helper TH17 cells implicated
in type 1 diabetes developmen t( 6 )a sw e l la si n c r e a s e d
expression of regenerative genes in b-cells. Interestingly,
T-cell numbers, regulatory T-cell activity and cytokine
production were normal in these mice, suggesting that
the effect was not a consequence of general immunosup-
pression as might be expected from the in vitro effects of
IL-21 (4). These ﬁndings were conﬁrmed and extended by
Sutherland et al. (7) in 2009, who showed that b-cell
overexpression of IL-21 caused inﬂammatory cytokine
and chemokine induction, insulitis, b-cell destruction, and
diabetes in nondiabetes-prone mice. Again, the lymphoid
compartment was normal, but IL-21R–deﬁcient spleno-
cytes failed to adoptively transfer diabetes to NOD/SCID
mice, indicating that IL-21 is essential for effector T-cell
competence. Taken together, previous work in this ﬁeld
pointed to the potential use of anti–IL-21 as a preventive
therapy in individuals at risk for type 1 diabetes, but did
not address the clinically important questions of whether
anti–IL-21 therapy reduces disease activity around the time
of diabetes onset when detecting a reduction in ﬁrst phase
insulin or overt diabetes would allow a more targeted
therapy.
This question was asked in the study of McGuire et al.
(8), taking advantage of a neutralizing IL-21R fusion pro-
tein (IL-21R/Fc) to block IL-21 activity in the NOD mouse
and of a model of islet allograft rejection in diabetic
IL-21r
2/2 recipient mice. The article adds three important
messages to current knowledge (Fig. 1): short-term anti–
IL-21 therapy alone is effective only just before diabetes
onset; the therapy together with a syngeneic islet graft
but not alone reverts overt diabetes, an effect maintained
after graft removal; and islet allograft rejection is sig-
niﬁcantly improved in IL-21 receptor–deﬁcient recipients,
an effect that was abolished in the presence of IL-21 re-
ceptor expressing and thereby responsive competent CD8
+
T-cells.
What are the mechanisms of action of IL-21 blockade
in these mouse models? IL-21 neutralization decreased
numbers of pancreatic and splenic TH17 T-cells and num-
bers of activated CD8
+ and CD4
+ T-cells in the pancreas
and pancreatic lymph nodes (5,8–10). The importance of
reduced IL-17 production and regulatory T-cells is de-
bated (5,7,8). McGuire et al. propose that a reduction in
IL-21–induced IL-21 contribute to the sustained effects of
short-term IL-21 neutralization (8). However, in IL-21r
-/-
mice, IL-21 production was sufﬁcient to induce a CD8+
T-cell–mediated graft destruction in adoptive transfer exper-
iments (8) indicating that a reduced IL-21 production per
se is dispensable for the protective effects of anti–IL-21.
Further, McGuire et al. did not examine b-cell expression
of regenerative genes found enhanced in IL-21r
2/2 mice
by others (5), but the adoptive transfer experiment (8)
suggests that IL-21–induced graft destruction is not de-
pendent on direct negative effects on b-cells, and in ad-
dition b-cells have not been found to express IL-21r (7).
Thus, more research is needed to clarify the mechanisms
of action, e.g., via which secondary mediator IL-21 in-
hibits b-cell reg gene expression.
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COMMENTARYLymphopenia has been suggested to precede diabetes
onset and result in homeostatic expansion of tissue-
destructive T-cells in the NOD mouse (11). IL-21 is im-
portant in this respect by inducing a rapid turnover and
thereby replicative senescence of T-cells (10,11). However,
lymphopenia is not found consistently in all NOD colonies
(12) and CD4
+ and CD8
+ T-cell numbers were not affected
in spleen and pancreatic lymph nodes of other IL-21r
2/2
NOD mice colonies (5,7). The study by McGuire et al. (8)
does not directly address this issue. However, because IL-21
is important for homeostatic expansion of tissue-destructive
T-cells preceding insulitis, the observation that IL-21 neu-
tralization reverses insulitis (8) points to other important
functions of IL-21 in the maintenance of islet inﬂammation.
Whereas the evidence reviewed above identiﬁes IL-21 as
a central cytokine in b-cell destruction in mouse models,
the relevance of these promising ﬁndings for the applica-
tion of anti–IL-21 therapy for type 1 diabetes in humans is
yet to be proven. IL-21 is being evaluated as a therapy in
metastatic melanoma and renal carcinoma, in non-Hodgkin’s
lymphoma and ovarian cancer, and anti–IL-21 is in phase I
trials for rheumatoid arthritis (13). Considering the unknown
long-term safety proﬁle of immunomodulatory agents such
as anti-CD3 (T-cell) or anti-CD20 (B-cell) antibodies and
IL-21 neutralization as well as the transience of remission
induced by some of these drugs, there is an urgent need for
studies to deﬁne the clinical beneﬁt of combining therapies
targeting key pathways in the inﬂammatory pathogenesis
of type 1 diabetes to increase safety and efﬁcacy. McGuire
et al. did not examine whether the adjuvant effect of islet
transplantation to the action of IL-21R/Fc is mimicked by
exogenous insulin. Thus, adding in treatments shown to
protect b-cell function directly or indirectly such as in-
tensive insulin treatment or anti–IL-1 may provide synergy
with therapies targeting mainly the immune system. Future
advances in this ﬁeld may become a game of the number
of the cytokines to be targeted as well as the number of
therapies in the combination.
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